Microsoft word - clarify about servier
– Backgrounder –
Servier is France’s leading independent pharmaceutical company and the country’s second largest drug company.
Servier is present in 140 countries worldwide. R&D at Servier spans a range of therapeutic fields, with the main areas of
focus being cardiovascular disease, neuroscience, oncology, metabolic disorders, and rheumatology. In the field of
cardiovascular disease in particular, Servier is one of the principal research organizations dedicated to the development
Servier has a long-standing interest in the field of cardiovascular disease. Nearly two thirds (63%) of Servier’s global
turnover from medicines is made up of drugs targeted at cardiovascular diseases.
Servier is unique among global pharmaceutical companies in that all the company’s cardiovascular products it has
introduced have stemmed from its own research efforts.
is the first and only specific and selective I
f current inhibitor of the sinus node. Procoralan was
approved in 2005 by the European regulatory authorities (EMEA) for clinical use in selected patients with chronic stable
angina. It is currently available in around 70 countries worldwide.
Servier’s cardiovascular portfolio also includes Coversyl® (perindopril),
Servier’s leading product for high blood
pressure, heart failure, and for the treatment of patients with stable coronary artery disease (CAD) to reduce the risk of
coronary events, Vastarel MR® (trimetazidine)
for stable angina and Preterax® (perindopril / indapamide)
Natrilix® SR (indapamide)
Servier and landmark clinical trials
Servier has been involved in several large-scale outcomes clinical trials for several years including the BEAUTIFUL
ion of the If
Inhibitor ivabradine in patients with coronary disease and left ventricUL
dysfunction) trial, which demonstrated the benefits of Procoralan (ivabradine) in reducing cardiovascular events in
patients with coronary artery disease (CAD) receiving current preventative therapy . The results of this trial have major
implications for the management of cardiovascular disease.
Other Servier trials include the ADVANCE
ction in D
iabetes and V
x and DiamicroN
valuation) study. This is the world’s largest prospective mortality/morbidity trial in patients with type 2
diabetes to date. The study demonstrated the effects of blood pressure lowering with Preterax®-based therapy1 and
intensive glucose-lowering with Diamicron MR-based therapy2 on the risk of complications in patients with type 2
The efficacy of perindopril alone and in combination has been investigated in a number of trials.
tudy) showed that perindopril 4 mg + indapamide 2.5 mg reduced the
risk of stroke by 29% in patients with a history of cerebrovascular disease.3
uropean trial on R
f cardiac events with P
erindopril in stable coronary A
showed that perindopril 8 mg is associated with a 20% reduction in the risk of cardiovascular death, myocardial
infarction, and cardiac arrest compared with placebo in patients with coronary heart disease.4
Other significant, independent, investigator-led trials include ASCOT-BPLA
5 in hypertension (amlodipine + perindopril),
6 in postmyocardial infarction in elderly (perindopril) and PEP-CHF
7 in diastolic heart failure (perindopril).
*Depending on the country, ivabradine is available as Procoralan®, Coralan®, Coraxan®, or Corlentor®
1. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular
outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet.
2007 ; 370 : 829-40.
2. ADVANCE collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med
. 2008 ;
3. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with
previous stroke or transient ischaemic attack. Lancet
2001 ; 358 : 1033-41.
4. Fox KM. European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in
reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled,
multicentre trial (the EUROPA study). Lancet.
2003 ; 362 : 762-68.
5. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril
as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet.
2005 ; 366 : 895-906.
6. The PREAMI Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodelling and clinical
outcome. Results of the Randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study. Arch Intern Med.
2006 ; 166 : 659-66.
7. PEP-CHF Investigators. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J.
2006 ; 27 : 2338-2445.
“‘Realität’ ist, was wir als wahr annehmen. Was wir als wahr annehmen, ist, was wirglauben. Was wir glauben, basiert auf unseren Wahrnehmungen. Was wirwahrnehmen, hängt davon ab, was wir suchen. Was wir suchen, hängt davon ab,was wir denken. Was wir denken, hängt davon ab, was wir wahrnehmen. Waswir wahrnehmen, bestimmt, was wir glauben. Was wir glauben, bestimmt, waswir für wahr h
Universidade Federal do Ceará Pró-Reitoria de Pesquisa e Pós-Graduação PIBIC 2012/2013 - Edital 01/12 Desenvolvimento e validação de métodos analíticos e estudo de estabilidade para avaliação de fosfomicina em matéria-prima e granulado A fosfomicina trometamol possui um amplo espectro antimicrobiano contra bactérias gram-positivase gram-negativas comumente associadas